Lisuride for levodopa-induced complications in Parkinson's disease.
OBJECTIVE
To compare the efficacy and safety of adjuvant lisuride therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.


METHODS
Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories and Roche Products Limited.


METHODS
Randomised controlled trials of lisuride versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.


METHODS
Data was to be abstracted independently by each author and differences settled by discussion.


RESULTS
No randomised controlled trials comparing lisuride with placebo in advanced Parkinson's disease with motor complications were found.


CONCLUSIONS
Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported.
Clarke
C E
CE
Department of Neurology, City Hospital NHS Trust, Dudley Road, Birmingham, West Midlands, United Kingdom, B18 7QH. c.e.clarke@bham.ac.uk
Speller
J M
JM
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008090:Lisuride / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007980:Levodopa; D008090:Lisuride